Powrót do kalendarium
Ostatnia aktualizacja: 2008-08-18
Biomarkers Europe 2008
Biomarkers Europe
* Clinical Biomarkers
* Pharmacogenomics
* Biomarker Assay Development
* Biomarkers in Clinical Pharmacology
* Biomarkers for Patient Selection
* Toxicity Biomarkers
* ‘Omic’ Biomarkers
* Regulatory Perspective
Preliminary Agenda:
Clinical Biomarkers
Biomarkers Predicting Clinical Benefit – Fact or Fiction?
Hans Winkler, Ph.D., Senior Director, Functional Genomics, Oncology, Johnson & Johnson Pharmaceutical R&D, Belgium
Influence of Bcl-2 Family Members on the Cellular Response to ABT-263, a Novel and Potent BH-3 Mimetic
Stephen Tahir, Ph.D., Research Investigator, Cancer, Abbott Laboratories
Target-Related Pharmacodynamic Analysis to Guide Successful Development of Biological Therapies: Novel Biomarker Concepts and Analytical Strategies
Miro Venturi, Ph.D., Head of PK/PD Assay Development Group, Novartis Biologics
Experimental Medicine and Marker Endpoints in Orphan Disease: The Motor Neuron Disease Example
Vincenzo Libri, M.D., Ph.D., Head of Experimental Medicine, Neuroscience CEDD, GlaxoSmithKline, UK
Title to be Announced
Hakan Wennbo, Ph.D., Director, Discovery Medicine, Cardiovascular/Gastrointestinal, AstraZeneca
‘Omic’ Biomarkers
Allelic Expression in Human Blood from A Depression Case/Control Collection: Assessing the Functional Impact of SNPs on A Genome-Wide Scale for The Identification of Novel Genetic-Driven Biomarkers
Enrico Domenici, Ph.D., Director, Molecular Psychiatry, GlaxoSmithKline Medicines Research Centre, Italy
From Protein Biomarker Discovery to Validation
Hanno Langen, Ph.D., Head, Proteomics Initiative, Roche Center for Medical Genomics
Principal Components of Single Drug Dose Toxicity Data Using 13C Tracer Substrate Based Metabolomics
Laszlo Boros, M.D., Associate Professor of Pediatrics, University of California Los Angeles; Co-Director, Stable Isotope Research Laboratory, Harbor-UCLA Medical Center; Chief Scientific Advisor, SiDMAP, LLC
Regulatory Perspective
Title to be Announced
Linda Surh, M.D., Ph.D., Director, CEDD Global Regulatory Affairs, Neurology and Pharmacogenetics, GlaxoSmithKline, UK
Biomarkers and Pharmacogenomics: A Regulatory Perspective
Krishna Prasad, Ph.D., Clinical Assessor, MHRA & Member, Pharmacogenetics Working Party, EMEA, UK
Biomarker Assay Development
Title to be Announced
Raffaella Castoldi, Ph.D., Head, Analytical Biology, Nerviano Medical Sciences, Italy
Multiplexing and New Technology Platforms – Impact and Comparison of Assay Validation Data
John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research
Technology Showcase
Combining Microvessel Density and Morphology with Protein Expression in Endothelial Cells to Characterize the Tumor Microenviroment
Steven J. Potts, Ph.D., M.B.A., Scientific Director, Biotechnology and Pharmaceutical, Aperio Technologies
in silico Biomarker Discovery
Frank Schacherer, Ph.D., Executive Vice President, BIOBASE GmbH
Pharmacodynamic Biomarkers in Early Phase Clinical Research
Rosalyn Forsey, Ph.D., Biomarker Specialist, LCG Bioscience
* Clinical Biomarkers
* Pharmacogenomics
* Biomarker Assay Development
* Biomarkers in Clinical Pharmacology
* Biomarkers for Patient Selection
* Toxicity Biomarkers
* ‘Omic’ Biomarkers
* Regulatory Perspective
Preliminary Agenda:
Clinical Biomarkers
Biomarkers Predicting Clinical Benefit – Fact or Fiction?
Hans Winkler, Ph.D., Senior Director, Functional Genomics, Oncology, Johnson & Johnson Pharmaceutical R&D, Belgium
Influence of Bcl-2 Family Members on the Cellular Response to ABT-263, a Novel and Potent BH-3 Mimetic
Stephen Tahir, Ph.D., Research Investigator, Cancer, Abbott Laboratories
Target-Related Pharmacodynamic Analysis to Guide Successful Development of Biological Therapies: Novel Biomarker Concepts and Analytical Strategies
Miro Venturi, Ph.D., Head of PK/PD Assay Development Group, Novartis Biologics
Experimental Medicine and Marker Endpoints in Orphan Disease: The Motor Neuron Disease Example
Vincenzo Libri, M.D., Ph.D., Head of Experimental Medicine, Neuroscience CEDD, GlaxoSmithKline, UK
Title to be Announced
Hakan Wennbo, Ph.D., Director, Discovery Medicine, Cardiovascular/Gastrointestinal, AstraZeneca
‘Omic’ Biomarkers
Allelic Expression in Human Blood from A Depression Case/Control Collection: Assessing the Functional Impact of SNPs on A Genome-Wide Scale for The Identification of Novel Genetic-Driven Biomarkers
Enrico Domenici, Ph.D., Director, Molecular Psychiatry, GlaxoSmithKline Medicines Research Centre, Italy
From Protein Biomarker Discovery to Validation
Hanno Langen, Ph.D., Head, Proteomics Initiative, Roche Center for Medical Genomics
Principal Components of Single Drug Dose Toxicity Data Using 13C Tracer Substrate Based Metabolomics
Laszlo Boros, M.D., Associate Professor of Pediatrics, University of California Los Angeles; Co-Director, Stable Isotope Research Laboratory, Harbor-UCLA Medical Center; Chief Scientific Advisor, SiDMAP, LLC
Regulatory Perspective
Title to be Announced
Linda Surh, M.D., Ph.D., Director, CEDD Global Regulatory Affairs, Neurology and Pharmacogenetics, GlaxoSmithKline, UK
Biomarkers and Pharmacogenomics: A Regulatory Perspective
Krishna Prasad, Ph.D., Clinical Assessor, MHRA & Member, Pharmacogenetics Working Party, EMEA, UK
Biomarker Assay Development
Title to be Announced
Raffaella Castoldi, Ph.D., Head, Analytical Biology, Nerviano Medical Sciences, Italy
Multiplexing and New Technology Platforms – Impact and Comparison of Assay Validation Data
John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research
Technology Showcase
Combining Microvessel Density and Morphology with Protein Expression in Endothelial Cells to Characterize the Tumor Microenviroment
Steven J. Potts, Ph.D., M.B.A., Scientific Director, Biotechnology and Pharmaceutical, Aperio Technologies
in silico Biomarker Discovery
Frank Schacherer, Ph.D., Executive Vice President, BIOBASE GmbH
Pharmacodynamic Biomarkers in Early Phase Clinical Research
Rosalyn Forsey, Ph.D., Biomarker Specialist, LCG Bioscience
Kategoria wydarzenia:
Z życia branży
Terminy wydarzenia
Organizator
CAMBRIDGE HEALTHTECH INSTITUTE
Julia Boguslavsky
- - Executive Director
- Adres: Vienna
- E-mail: juliab@healthtech.com
Przy kontakcie powołaj się na portal laboratoria.xtech.pl
RSS